Cerebral vasospasm is a deadly complication following the rupture of intracranial aneurysms. One new development in the experimental treatment of cerebral vasospasm is the looming target of signaling pathways. The pathogenesis of cerebral vasospasm involves multiple signaling pathways in proliferation, in ammation, cell death, smooth muscle phenotype changes, vascular remodeling, and contraction. A review of all of these areas is beyond the scope of this article, and as such, three systems that mediate these vascular responses have been selected: the tyrosine kinase-MAP kinase pathway, the sphingosine-1-Rho myosin light chain kinase pathway and protein kinase C.
Introduction
Cerebral vasospasm is a deadly complication following the rupture of intracranial aneurysms. 4, 19, 23, 28 e time course of cerebral vasospasm is unique in that it is slow developing, usually takes 4-7 days to peak, but lasts up to 2-3 weeks, and is resistant to most known vasodilators. 4, 23, 27 ese special features make cerebral vasospasm the most important determinant in the outcome of patients su ering subarachnoid hemorrhage. Vasospasm adversely a ects 10% to 20% of patients with aneurysmal SAH. 4, 5, 7, 11, 15, 19 Although it is present on catheter angiograms in 40% to 70% of patients with SAH, only 20% to 30% will develop clinical vasospasm. 11, 15, 27, 28 Up to 15% of patients surviving the ictus of SAH experience stroke or death from vasospasm despite maximal medical therapy, including hemodynamic therapy and nimodipine. 4, 7, 27, 28 e available treatment strategies include mechanical dilation of spastic cerebral arteries (angioplasty) and non-selective vasodilatation such as by Ca 2+ channel blockers. 4, 7, 9, 15, 27, 28 One new development in the experimental treatment of cerebral vasospasm is the looming target of signaling pathways. Understanding vasospastic signals in cerebral arteries might o er a new avenue for selective treatment of cerebral vasospasm in the future.
e pathogenesis of cerebral vasospasm involves multiple signaling pathways in proliferation, in ammation, cell death, smooth muscle phenotype changes, vascular remodeling, and contraction. 20, 22, 24 A review of all of these areas is beyond the scope of this article, and as such, two systems that mediate these vascular responses have been selected: the tyrosine kinase-MAP kinase pathway and the sphingosine-1-Rho myosin light chain kinase pathway. Papers related to endothelin, nitric oxide, free radicals and gene therapy are not included in this review.
Tyrosine kinase and mitogenactived protein (MAP) kinase MAP kinase has been suggested to be one of the most important signaling pathways involved in cerebral vasospasm based in part on the role of MAP kinase in cell di erentiation, proliferation, contraction, death and remodeling. 1 MAP kinase is involved in the regulation of CA 2+ in cerebral smooth muscle cells and in the contraction of cerebral arteries.
1,2,10 Blood clot components including hemoglobin and vasoactive agents released from the vessel wall such as endothelin-1 enhance MAP kinase expression and activity in cerebral arteries. Free radicals activate MAP kinase in vascular smooth muscle cells. MAP kinase inhibitors were reported to decrease MAP kinase expression in vasospastic arteries and to reduce the degree of cerebral vasospasm in animal models. 1 A recent study 1 demonstrated that antisense oligodeoxunucleotides to MAP kinase abolished MAP kinase activity and phosporylated MAP kinase and reduce vasospasm in a rat model of subarachnoid hemorrhage. 1, 10 Because MAP kinase is a substrate of tyrosine kinase, the possible role of tyrosine kinase as an upstream modulator of MAP kinase in cerebral vasospasm needs to be addressed. 6 Tyrosine kinase regulates intracellular Ca 2+ and smooth muscle contraction induced by spasmogens including blood clot components and vasoactive agents. 1, 6, 24 Tyrosine kinase is involved in the compaction of broblasts. Some G-protein coupled receptor agonist and growth factors activate tyrosine kinase. e level of these G-protein receptor agonist such as adenosine triphosphate and endothelins, growth factors, and their receptors are increased in cerebrospinal uid or in cerebral arteries. 1 Tyrosine activation phosphorylates other substrates such as Ras protein and phosphatidyl inositol-3 kinase tyrosine kinase. Ras is increased a er spasmogen stimulation, and phospatidyl-inositol-3 kinase is enhanced a er vasospasm in animals. e tyrosine kinase inhibitors sumarin but not phosphatidylinositol-3-kinase inhibitors reduced vasospasm in animal models. 1, [16] [17] [18] 24 Overall, MAP kinase and particularly the extracelular regulated kinase (ERK) system is involved in proliferation, di erentiation, and contraction of cerebral arteries a er subarachnoid hemorrhage.
Sphingosine-1 and Rho/ myosin light chain kinase
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that is known to mediate diverse cellular responses including cell growth, survival, and migration. 2, 24 Most of these e ects have been attributed to its binding to a speci c subfamily of G protein--coupled receptors (GPCR), namely S1P. Recent studies have suggested that S1P also plays a prominent role in the contraction of various types of smooth muscle.
is review provides a brief overview of its role in this process and also highlights how S1P-dependent signaling serves as an important regulator of smooth muscle contraction.
2,24
Sphingosine 1-phosphate (S1P) is stored in platelets and released on their activation. Similar to MAP kinase, many stimuli such as growth factors, cytokines, G-protein coupled receptors coupled receptor agonist, and antigens have been shown to increase sphingosine kinase activity and SP1 formation in di erent cell types, including smooth muscle cells. Indeed, SP1 has been implicated in the regulation of several important cellular processes, such as proliferation, di erentiation, apoptosis and migration in these cells. 2, 24 Sphingosylphosphorylcholine (SPC), a sphingolipid, is a novel messenger for Rho kinase-mediated Ca 2+ sensitization in the bovine cerebral artery but not for protein kinase C. Rho and Rho kinase are believed to play roles in smooth muscle contraction and cytoskeleton reorganization. Rho kinase, wich is activated by the small guanosine triphosphatase. Rho, phosphorylates not only myosin light chain but also myosin phosphatase at its myosin binding subunit, thus inactivating myosin phosphatase.
Protein kinase C Twenty-ve years a er the discovery of protein kinase C (PKC), the physiologic function of PKC, and especially its role in pathologic conditions, remains a subject of great interest. In the cerebral circulation, PKC plays a role in the regulation of myogenic tone by sensitization of myo laments to calcium. Protein kinase C phosphorylates various ion channels including augmenting voltage-dependent Ca 2+ channels and inhibiting K+ channels, which both lead to vessel contraction. ese actions of PKC amplify vascular reactivity to di erent agonists and may be critical in the regulation of cerebral artery tone during vasospasm. 8, 18, 24 Evidence accumulated during at least the last decade suggests that activation of PKC in cerebral vasospasm results in a delayed but prolonged contraction of major arteries a er subarachnoid hemorrhage. Most of the experimental results in vitro or in animal models support the view that PKC is involved in cerebral vasospasm. Implication of PKC in cerebral vasospasm helps explain increased arterial narrowing at the signal transduction level and alters current perceptions that the pathophysiology is caused by a combination of multiple receptor activation, hemoglobin toxicity, and damaged neurogenic control. 8, 18, 21, 24, 25 Activation of protein kinase C also interacts with other signaling pathways such as myosin light chain kinase, nitric oxide, intracellular Ca 2+ , protein tyrosine kinase, and its substrates such as mitogen-activated protein kinase. Even though identifying PKC revolutionized the understanding of cerebral vasospasm, clinical advances are hampered by the lack of clinical trials using selective PKC inhibitors. 2, 7, 10, 13, 18 PKC may be involved in the initial contraction but not late stages contraction (vasospasm) in animal models. Degradation of the thin lament associated protein calponin in spastic arteries in an animal model has been reported. HA1077, an inhibitor of protein kinases, including Rho kinase and myosin light chain kinase, reduted vasospasm and calponin degradation in this model.
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Others signaling pathways
Other signaling pathways that may be involved in the vasospasm include those activated by or involved in the contraction of cerebral arteries related to endothelin, 3 
